KR102273075B1 - Composition for improving respiratory diseases using the extract of Chrysosplenium grayanum - Google Patents

Abstract

The present invention discloses a composition for improving lung diseases, such as chronic obstructive pulmonary disease, using an extract of black oxeye. Blackhorn extract inhibits the netosis activation of neutrophil extracellular traps induced by PMA (phorbol myristate acetate), and inflammatory astrocytes caused by CSE of NCI-H292 cells, a bronchial epithelial cell line that produces mucin. It suppresses the expression of the kinase IL-8, and has the activity of suppressing the expression of MIP-2, an inflammatory cytokine, in MH-S cells, which are alveolar macrophages activated by CES and LPS (lipopolysaccaride).

Description

Composition for improving respiratory diseases using the extract of Chrysosplenium grayanum

The present invention relates to a composition for improving chronic obstructive pulmonary disease using an extract of black oxeye.

Chronic obstructive pulmonary disease (COPD) is a chronic airway disease that presents with coughing, sputum, breathing difficulties, decreased expiratory flow rate, and gas exchange disorder. It is predicted to become the third leading cause of human death in 2018 (Am J Respir Crit Care Med, 2013, 187:347-365; Am J Respir Crit Care Med, 2009, 180:396-406).

COPD is caused by various causes such as smoking, air pollution, chemicals, occupational factors, and genetic predisposition. Pharm Bull, 2012, 35:1752-1760). In the pathogenesis of COPD, inflammation, protease activation in the lungs, oxidative stress, etc. are involved, and cells involved in inflammation are mainly neutrophils, macrophages, and T lymphocytes. These inflammatory cells produce reactive oxygen species, various inflammatory cytokines, and several proteolytic enzymes that cause tissue damage (Korea Tuberculosis and Respiratory Association Psoriasis Seoul: Gunja Publishing House; 2007, p 301-5; Am J Respir Crit Care Med, 1997 155, 1441-1447; Am J Physiol Lung Cell Mol Physiol, 2010, 298:L262-L269). In particular, neutrophils secrete substances such as elastase, collagenase, proteases such as MPO (myeloperoxidase), arachidonic acid metabolites (arachidonate) and reactive oxygen free radicals to the lungs. It is known that it plays an important role in the pathogenesis of COPD by causing damage, and thus has become an important target in the development of a therapeutic agent for COPD (Am J Respir Cell Mol Biol, 2013, 48:531-539; Eur Respir J, 1998, 12:1200-1208).

Recently, it has been reported that netosis activation of neutrophil extracellular traps is involved in the pathogenesis of chronic lung/respiratory diseases including COPD (PLoS One. 2014 May 15; 9(5): e97784). .; Respir Res. 2015 May 22;16:59.; J Immunol Res. 2017;2017:6710278; Respirology. 2016 Apr; 21(3):467-75).

There have been no reports of drugs that directly improve COPD, etc., and the current COPD treatment is to reduce symptoms and complications, such as bronchodilators (β2-agonists, anticholinergics, methylxanthines) and steroids (inhalation, oral). This is mainly used.

It is an object of the present invention to provide a food composition for enhancing respiratory function and improving respiratory diseases using the extract, a health functional food containing the food composition, and a pharmaceutical composition for preventing or treating respiratory diseases using the extract Other objects or specific objects of the present invention will be set forth below.

As confirmed in the Examples and Experimental Examples below, the present inventors inhibited the activation of netosis of neutrophil extracellular traps induced by PMA (phorbol myristate acetate), and the bronchial extract, as confirmed in the Examples and Experimental Examples below. Inhibits the expression of IL-8, an inflammatory cytokine, by CSE in NCI-H292 cells, an epithelial cell line, and MIP-2, an inflammatory cytokine, also in MH-S cells, which are alveolar macrophages activated by CES and LPS (lipopolysaccharide). It was confirmed that the expression was inhibited.

In consideration of the above, the present invention, in one aspect, can be identified as a composition for improving COPD comprising an extract from the eye of black ox as an active ingredient, and in another aspect, enhancement of respiratory function and the respiratory system comprising an extract from the eye of a hoeae as an active ingredient It can also be identified as a composition for improving diseases, and the present invention also includes a black oxeye extract as an active ingredient, coughing, sputum, dyspnea, airway hypersensitivity, airway obstruction, mucus hypersecretion, decrease in exhaled flow rate and/or disturbance of gas exchange It can also be identified as a composition for improving lung disease accompanying symptoms. These lung diseases include not only the aforementioned COPD, but also diffuse interstitial lung disease, acute respiratory distress syndrome (ARDS), and acute lung injury, and regardless of the cause, the aforementioned smoking, air pollution, In addition to lung diseases caused by genetic predisposition, in particular, lung diseases caused by fine dust, which has become a problem recently, are included. Fine dust containing various components such as carbon components such as soot and organic carbon, ionic components such as chlorine, nitric acid, ammonium, sodium and calcium, metal components such as lead, arsenic and mercury, and polycyclic aromatic hydrocarbons such as benzopyrene It is known to cause various lung diseases such as asthma and COPD by depositing in the respiratory tract, bronchi, small airways, and alveoli (J Korean Med Assoc, 2014; 57: 763-768).

As used herein, the term "extract" refers to the stem, leaf, fruit, flower, root, or mixture thereof of a plant to be extracted with water, lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.), methylene chloride, ethylene, Using acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof It means an extract obtained by leaching, an extract obtained by using a supercritical extraction solvent such as carbon dioxide, pentane, or a fraction obtained by fractionating the extract, and the extraction method is cold immersion, reflux, Any method such as heating, ultrasonic radiation, or supercritical extraction may be applied. In the case of the fractionated extract, a fraction obtained by suspending the extract in a specific solvent and mixing and standing still with a solvent having a different polarity, and adsorbing the crude extract to a column filled with silica gel, etc., hydrophobic solvent, hydrophilic solvent, or a mixed solvent thereof It is meant to include the fraction obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or solid extract from which the extraction solvent has been removed by freeze drying, vacuum drying, hot air drying, spray drying, or the like. Preferably, it means an extract obtained by using water, ethanol, or a mixed solvent thereof as an extraction solvent, and more preferably an extract obtained by using a mixed solvent of water and ethanol as an extraction solvent.

In addition, as used herein, the term "active ingredient" refers to a component capable of exhibiting the desired activity alone or in combination with a carrier having no activity by itself.

In the present invention, the term "enhancement of respiratory function" refers to maintaining the original functions of respiratory organs such as nasal passages, pharynx, larynx, trachea, bronchial tubes and lungs in a healthy state, or according to smoking, fine dust, neutrophil neutrophil activation or other respiratory diseases. It refers to any action that improves the function of the respiratory organs, which has been deteriorated due to symptoms, to the original healthy state.

In addition, in the present invention, the "respiratory disease" means a disease occurring in the respiratory tract of an individual, such as the nasal cavity, pharynx, larynx, trachea, bronchi, and lung. Specifically, the respiratory disease is a respiratory disease caused by smoking or fine dust. ; Or it may mean a lung disease accompanied by netosis (Netosis), but is not particularly limited thereto. More specifically, the respiratory disease may refer to a lung disease accompanied by symptoms of sputum, dyspnea, airway hypersensitivity, airway obstruction, mucus hypersecretion, decreased expiratory flow rate and/or impaired gas exchange, and more specifically asthma , chronic obstructive pulmonary disease (COPD), tracheitis, bronchitis, diffuse interstitial lung disease, acute respiratory distress syndrome (ARDS), acute lung injury, cystic fibrosis, capillary Bronchitis (bronchiolitis), influenza virus infection (influenza virus infection), pneumonia (pneumonia), tuberculosis (tuberculosis) and transfusion-related acute lung injury (transfusion-related acute lung injury) may mean one or more selected from the group consisting of, , most specifically COPD. On the other hand, it has recently been reported that activation of netosis of neutrophil extracellular traps is involved in the pathogenesis of chronic respiratory diseases including COPD.

In the composition of the present invention, the active ingredient may be used in any amount according to the specific use, formulation, purpose of formulation, etc. as long as it can exhibit anti-inflammatory activity, COPD improvement activity, other lung disease improvement activity, respiratory function enhancement and respiratory disease improvement activity. (effective amount), a typical effective amount will be determined within the range of 0.001 weight % to 20.0 weight % based on the total weight of the composition. As used herein, the term "effective amount" refers to the intended functional and pharmacological effects, such as COPD improvement effect, when the composition of the present invention is administered to a mammal, preferably a human, to which it is applied during the administration period as suggested by a medical professional. Refers to the amount of the active ingredient contained in the composition of the present invention. Such effective amounts can be determined empirically within the ordinary ability of one of ordinary skill in the art.

Subjects to which the composition of the present invention can be applied (prescribed) are mammals and humans, particularly preferably humans.

The composition of the present invention, in addition to the active ingredient, in order to enhance the convenience of administration or intake through addition of similar activities such as anti-inflammatory activity, anti-allergic activity, etc., safety has already been verified in the art and any known to have the activity It may further include a compound or natural extract of

Such compounds or extracts include compounds or extracts, drugs listed in compendial documents such as pharmacopeias of each country (“Korean Pharmacopoeia” in Korea) and health functional food regulations of each country (“health functional food standards and specifications” announced by the Ministry of Food and Drug Safety in Korea). Each country's laws governing the manufacture and sale of compounds, extracts, and health functional foods that have been approved for items in accordance with the laws of each country (the "Pharmaceutical Act" in Korea) that regulate the manufacture and sale of '), a compound or extract whose functionality is recognized may be included.

For example, MSM (dimethylsulfonylmethane), N-acetylglucosamine, etc., which are recognized for their anti-inflammatory (“arthritis improvement”) functions, and anti-allergic (“relief of hypersensitive immune response”) functions are recognized in accordance with the Korean 「Health Functional Food Act」 Enterococcus faecalis heat-treated dry powder, complexes such as guava leaf extract, Actinidia extract, leaf extract, picaopreto powder, etc., PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), etc. It may correspond to a compound or an extract, but is not particularly limited thereto.

One or more of these compounds or natural extracts may be included in the composition of the present invention together with the active ingredient.

In a specific aspect, the composition of this invention can be grasped|ascertained as a food composition. In addition, the food of the present invention may include health functional (sex) food. In the present invention, the term "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients useful for the human body. Here, the term "functionality" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, if the formulation of the health functional food is also recognized as a health functional food, it may be manufactured without limitation. The food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur during long-term administration of the drug using food as a raw material, and has excellent portability, Health functional food can be taken as a supplement to enhance the effect of improving COPD, further enhancing respiratory function and improving respiratory disease.

The food composition of the present invention may be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, and ionic beverages, processed oils such as milk and yogurt, gums, rice cakes, Korean sweets, bread, Foods such as confectionery and noodles, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, and the like can be manufactured into health functional food preparations.

In addition, the food composition of the present invention may have any product classification as long as it conforms to the enforcement regulations at the time of manufacture and distribution in legal and functional classification. For example, it is a health functional food according to Korea's "Health Functional Food Act", or confectionery, beans, tea, and beverages according to each food type according to the Food Ordinance of Korea's Food Sanitation Act (Ministry of Food and Drug Safety Notification "Food Standards and Specifications") , food for special use, and the like.

The food composition of the present invention may contain food additives in addition to the active ingredients thereof. Food additives can be generally understood as substances that are added to and mixed with or infiltrated into food in manufacturing, processing or preserving food. Since they are consumed daily and for a long period of time with food, their safety must be ensured. Food additives with guaranteed safety are limited in terms of ingredients or functions in the Food Additives Ordinance in accordance with the laws of each country that regulates the manufacture and distribution of food (“Food Sanitation Act” in Korea). In the Korean Food Additives Code (“Food Additive Standards and Specifications” notified by the Ministry of Food and Drug Safety), food additives are classified into chemically synthetic products, natural additives, and mixed preparations in terms of ingredients. It is divided into agents, preservatives, emulsifiers, acidulants, thickeners, etc.

The sweetener is used to impart appropriate sweetness to food, and natural or synthetic ones may be used. Preferably, a natural sweetener is used. Examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavoring agents may be used to improve taste or aroma, and both natural and synthetic ones may be used. Preferably, it is a case where a natural thing is used. In the case of using a natural one, the purpose of nutritional enhancement in addition to flavor may be concurrently used. As a natural flavoring agent, it may be obtained from apple, lemon, tangerine, grape, strawberry, peach, etc., or it may be obtained from green tea leaf, dandelion, bamboo leaf, cinnamon, chrysanthemum leaf, jasmine, etc. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo biloba, etc. can be used. The natural flavoring agent may be a liquid concentrate or a solid extract. In some cases, a synthetic flavoring agent may be used, and the synthetic flavoring agent may include esters, alcohols, aldehydes, terpenes, and the like.

As a preservative, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. can be used, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, and pectin can be used. acidulant, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid and the like may be used as acidulants. Acidulant may be added so that the food composition has an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing the taste.

As the thickening agent, a suspending agent, a settling agent, a gel-forming agent, a bulking agent, and the like can be used.

The food composition of the present invention may contain, in addition to the food additives as described above, physiologically active substances or minerals known in the art for the purpose of supplementing and reinforcing functionality and nutrition and guaranteed stability as food additives.

Examples of such physiologically active substances include catechins contained in green tea and the like, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like. Magnesium preparations, such as iron preparations, such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc, etc. are mentioned.

In the food composition of the present invention, the food additives as described above may be included in an appropriate amount to achieve the purpose of the addition according to the type of product.

In relation to other food additives that may be included in the food composition of the present invention, reference may be made to the national food regulations or food additives regulations.

The composition of the present invention may be identified as a pharmaceutical composition in another specific embodiment.

The pharmaceutical composition of the present invention may be prepared as an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. Here, the route of administration may be any suitable route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of the combination of two or more routes is a case in which two or more formulations of drugs according to the route of administration are combined. For example, one drug is first administered by an intravenous route and the other drug is secondarily administered by a local route.

Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or formulation, and specifically, reference may be made to the pharmacopeias of each country including the "Korea Pharmacopoeia".

When the pharmaceutical composition of the present invention is prepared as an oral dosage form, powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, suspensions, wafers, together with a suitable carrier according to methods known in the art. It can be prepared in a formulation such as Examples of suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Cellulose such as hydroxypropylmethylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, grease Serol etc. are mentioned. In the case of formulation activity, an appropriate binder, lubricant, disintegrant, colorant, diluent, etc. may be included as needed. Suitable binders include starch, magnesium aluminum silicate, starch ferrist, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, and the like, and oleic acid as lubricant. sodium, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, magnesium salts and calcium salts thereof, polyethylene glycol, etc., and the disintegrant include starch, methyl cellulose , agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt. Examples of the diluent include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, and the like.

When the pharmaceutical composition of the present invention is prepared for parenteral use, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories together with suitable carriers according to methods known in the art. When formulated as an injection, an aqueous isotonic solution or suspension may be used as a suitable carrier, and specifically, PBS (phosphate buffered saline) containing triethanolamine, sterile water for injection, or isotonic solution such as 5% dextrose may be used. . When formulated for transdermal administration, it can be formulated in the form of ointments, creams, lotions, gels, external solutions, pasta agents, liniment agents, air rolls, and the like. In the case of a nasal inhalant, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc., and when formulated as a suppository, the carrier is Witepsol ( witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters, and the like can be used.

Specific formulations of pharmaceutical compositions are known in the art, and reference may be made to, for example, Remington's Pharmaceutical Sciences (19th ed., 1995). This document is considered a part of this specification.

A preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, patient's severity, and administration route. It can be in the range /kg. Administration may be performed once or divided into several times a day. Such dosages should not be construed as limiting the scope of the invention in any respect.

As described above, according to the present invention, it is possible to provide a composition for improving COPD using an extract of black oxeye. The composition of the present invention is commercialized as a food, particularly a health functional food or drug, and can be usefully used for the effect of improving COPD, further enhancing respiratory function and improving respiratory disease, coughing, sputum, difficulty breathing, airway hypersensitivity, It can also be usefully used for the improvement effect of other lung diseases accompanied by symptoms such as airway obstruction and mucus hypersecretion, such as diffuse interstitial lung disease, acute respiratory distress syndrome (ARDS), and acute lung injury.

1 shows the results of evaluating the IL-8 inhibitory activity of H292 cells in the treatment of each concentration of the extract of black oxeye.
Figure 2 shows the results of evaluating the MIP-2 inhibitory activity in the treatment of each concentration of the extract of black oxeye for MH-S cells.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these Examples and Experimental Examples.

[Example] Sample preparation

The activity of improving lung disease was confirmed by preparing an extract of black oxeye (extraction site: whole plant). The extract was obtained in powder form by adding 10 times the weight of 70% ethanol to the dry powder of the natural product to be extracted, extracting it twice at 50° C. for 6 hours, filtration, and then concentrating under reduced pressure and freeze-drying.

[Experimental Example] Lung disease improvement activity

Experimental Example 1: Netosis inhibitory activity of neutrophil cells

In order to measure the netosis activity of neutrophils, HL-60 (Human promyelocytic leukemia cells) cells purchased from the Korean cell line bank were used for the experiment. HL-60 cells were treated with 1% DMSO-treated RPMI (10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin) medium at 2×10 ⁵ cells/mL and incubated at 37°C, 5% CO2. ) was cultured for 5 days to differentiate to a mature neutrophil phenotype. After 5 days of centrifugation at 1,300 rpm for 5 minutes, 10 mL of HBSS (with Mg+, Ca+, Hanks' balanced salt solution) was treated, followed by centrifugation at 1,300 rpm for 5 minutes, followed by washing. Next, 2×10 ⁶ cell/mL was diluted in HBSS and aliquoted by 50 μL, each of the samples prepared at each concentration was treated by 50 μL, and PMA (in HBSS) prepared at 200 nM was treated with 100 μL each. After treatment in the well of 3 hours incubated (final PMA concentration 100nM). After 3 hours, Cytox green was treated with 500 nM and measured at a wavelength of 485/520 nm (excitation/emission maxima) using a fluorescence plate reader. The netosis activity of each sample was measured as a percentage compared to the PMA-treated control group (experimental control group), and the average value was expressed as a percentage.

As a result, it was confirmed that the black oxeye extract exhibited Netosis inhibitory activity (0.9% at 25 μg/mL, 9.5% at 50 μg/mL) when treated at a concentration of 25 μg/mL or more (Table 1).

Black Eye Treatment Concentration 25 μg/mL 50 μg/mL Netosis inhibitory activity (%) 0.9 9.5

Experimental Example 2: Evaluation of IL-8 inhibitory activity using H292 cells

^{H292 cells prepared at a concentration of 2×10 5} cells/mL in a 24-well plate were subcultured at 500 μL/well, and when the cells became more than 80% confluent, they were replaced with serum-free RPMI1640 medium and starvated for 24 hours. Thereafter, stimulants (CSE; final 2% or PPE; final 0.01 U/mL or PM2.5; final 10 μg/mL) and samples (final; 6.25, 12.5 μg/mL) were added using serum-free RPMI1640 medium. After dilution reflecting the desired final concentration, 500 uL per well was treated. After overnight incubation, the supernatant was recovered and used for IL-8 measurement. Human IL-8 was measured by the ELISA method, and was performed according to the protocol of the manufacturer (BD).

As a result, it was confirmed that the IL-8 concentration was inhibited in a concentration-dependent manner (6.25 μg/ml, 12.5 μg/ml) of the treated black oxeye extract ( FIG. 1 ).

Experimental Example 3: Evaluation of MIP-2 inhibitory activity using MH-S cells

The MH-S cell line was purchased from ATCC, and the medium composition used for culture was RMPI-1640 (WELGENE, cat. LM 011-01), 10% FBS (WELGENE, cat. S 001-07), 1% Penicillin- Streptomycin (WELGENE, cat. LS 202-02), 14.3 mM 2-Mercptoethanol (SIGMA). MH-S cells were seeded in a cell culture 96 well plate (SPL, cat. 30096) at a concentration of ^{5x10 4 /well and cultured for 24 hours.} After that, dilute the stimulant (CSE; final 1% and LPS; final 10 ng/mL) and sample (final; 25, 50, 100 μg/mL) with MH-S cell culture medium to reflect the desired final concentration and dilute the wells. 250 uL of each was treated. After incubation for 24 hours, the supernatant was recovered and used for MIP-2 measurement. MIP-2 was measured by ELISA method, and proceeded according to the protocol of the manufacturer (R&D, DY452).

As a result, it was confirmed that the concentration of MIP-2 was inhibited in a concentration-dependent manner (25 μg/ml, 50 μg/ml, 100 μg/ml) of the treated blackhorn extract ( FIG. 2 ).

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.

Claims (10)

As a food composition for improving respiratory diseases, comprising an extract of black oxeye as an active ingredient,
The respiratory disease is cystic fibrosis, chronic obstructive pulmonary disease (COPD), tuberculosis, pneumonia, bronchiolitis, transfusion-related acute pulmonary disease, or diffuse interstitial lung disease, the composition. The composition according to claim 1, wherein the extract is water, ethanol, or a mixed solvent extract thereof. delete delete The composition of claim 1 , wherein the respiratory disease is COPD. A health functional food comprising the food composition of claim 1, 2 or 5. As a pharmaceutical composition for the prevention or treatment of respiratory diseases, comprising the black oxeye extract as an active ingredient,
The respiratory disease is cystic fibrosis, chronic obstructive pulmonary disease (COPD), tuberculosis, pneumonia, bronchiolitis, transfusion-related acute pulmonary disease, or diffuse interstitial lung disease, the composition. The composition according to claim 7, wherein the extract is water, ethanol, or a mixed solvent extract thereof. delete 8. The composition of claim 7, wherein the respiratory disease is COPD.

Images